Multiple myeloma: Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)

A. Palumbo, S. Bringhen, A. Bertola, F. Cavallo, P. Falco, M. Massaia, B. Bruno, C. Rus, A. Barbui, T. Caravita, P. Musto, N. Pescota, F. Rossini, M. Vignetti, Mario Boccadoro

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Several trials have shown the superior impact of high-dose melphalan (usually 200mg/m2, MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100mg/m2, MEL100) is also superior to the standard dose, but has not been clinically compared with MEL200. A total of 90 patients at diagnosis were treated with two MEL100 courses. Their clinical outcome was compared with that of a control group of 90 pair mates matched for serum β2-microglobulin levels and Durie and Salmon clinical stage. These patients were treated at diagnosis with two MEL200 courses. Patient characteristics were similar in both groups except that the median age of the MEL100 group was significantly higher (P

Original languageEnglish
Pages (from-to)133-138
Number of pages6
JournalLeukemia
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 2004

Fingerprint

Melphalan
Multiple Myeloma
Salmon
Age Groups
Control Groups
Serum
Therapeutics

Keywords

  • Dose-intensive
  • Melphalan
  • Myelomatransplantation

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Palumbo, A., Bringhen, S., Bertola, A., Cavallo, F., Falco, P., Massaia, M., ... Boccadoro, M. (2004). Multiple myeloma: Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2). Leukemia, 18(1), 133-138. https://doi.org/10.1038/sj.leu.2403196

Multiple myeloma : Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2). / Palumbo, A.; Bringhen, S.; Bertola, A.; Cavallo, F.; Falco, P.; Massaia, M.; Bruno, B.; Rus, C.; Barbui, A.; Caravita, T.; Musto, P.; Pescota, N.; Rossini, F.; Vignetti, M.; Boccadoro, Mario.

In: Leukemia, Vol. 18, No. 1, 01.2004, p. 133-138.

Research output: Contribution to journalArticle

Palumbo, A, Bringhen, S, Bertola, A, Cavallo, F, Falco, P, Massaia, M, Bruno, B, Rus, C, Barbui, A, Caravita, T, Musto, P, Pescota, N, Rossini, F, Vignetti, M & Boccadoro, M 2004, 'Multiple myeloma: Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)', Leukemia, vol. 18, no. 1, pp. 133-138. https://doi.org/10.1038/sj.leu.2403196
Palumbo A, Bringhen S, Bertola A, Cavallo F, Falco P, Massaia M et al. Multiple myeloma: Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2). Leukemia. 2004 Jan;18(1):133-138. https://doi.org/10.1038/sj.leu.2403196
Palumbo, A. ; Bringhen, S. ; Bertola, A. ; Cavallo, F. ; Falco, P. ; Massaia, M. ; Bruno, B. ; Rus, C. ; Barbui, A. ; Caravita, T. ; Musto, P. ; Pescota, N. ; Rossini, F. ; Vignetti, M. ; Boccadoro, Mario. / Multiple myeloma : Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2). In: Leukemia. 2004 ; Vol. 18, No. 1. pp. 133-138.
@article{60edc1d9120f4fb383f0569d6759df6d,
title = "Multiple myeloma: Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)",
abstract = "Several trials have shown the superior impact of high-dose melphalan (usually 200mg/m2, MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100mg/m2, MEL100) is also superior to the standard dose, but has not been clinically compared with MEL200. A total of 90 patients at diagnosis were treated with two MEL100 courses. Their clinical outcome was compared with that of a control group of 90 pair mates matched for serum β2-microglobulin levels and Durie and Salmon clinical stage. These patients were treated at diagnosis with two MEL200 courses. Patient characteristics were similar in both groups except that the median age of the MEL100 group was significantly higher (P",
keywords = "Dose-intensive, Melphalan, Myelomatransplantation",
author = "A. Palumbo and S. Bringhen and A. Bertola and F. Cavallo and P. Falco and M. Massaia and B. Bruno and C. Rus and A. Barbui and T. Caravita and P. Musto and N. Pescota and F. Rossini and M. Vignetti and Mario Boccadoro",
year = "2004",
month = "1",
doi = "10.1038/sj.leu.2403196",
language = "English",
volume = "18",
pages = "133--138",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Multiple myeloma

T2 - Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)

AU - Palumbo, A.

AU - Bringhen, S.

AU - Bertola, A.

AU - Cavallo, F.

AU - Falco, P.

AU - Massaia, M.

AU - Bruno, B.

AU - Rus, C.

AU - Barbui, A.

AU - Caravita, T.

AU - Musto, P.

AU - Pescota, N.

AU - Rossini, F.

AU - Vignetti, M.

AU - Boccadoro, Mario

PY - 2004/1

Y1 - 2004/1

N2 - Several trials have shown the superior impact of high-dose melphalan (usually 200mg/m2, MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100mg/m2, MEL100) is also superior to the standard dose, but has not been clinically compared with MEL200. A total of 90 patients at diagnosis were treated with two MEL100 courses. Their clinical outcome was compared with that of a control group of 90 pair mates matched for serum β2-microglobulin levels and Durie and Salmon clinical stage. These patients were treated at diagnosis with two MEL200 courses. Patient characteristics were similar in both groups except that the median age of the MEL100 group was significantly higher (P

AB - Several trials have shown the superior impact of high-dose melphalan (usually 200mg/m2, MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100mg/m2, MEL100) is also superior to the standard dose, but has not been clinically compared with MEL200. A total of 90 patients at diagnosis were treated with two MEL100 courses. Their clinical outcome was compared with that of a control group of 90 pair mates matched for serum β2-microglobulin levels and Durie and Salmon clinical stage. These patients were treated at diagnosis with two MEL200 courses. Patient characteristics were similar in both groups except that the median age of the MEL100 group was significantly higher (P

KW - Dose-intensive

KW - Melphalan

KW - Myelomatransplantation

UR - http://www.scopus.com/inward/record.url?scp=10744225243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744225243&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403196

DO - 10.1038/sj.leu.2403196

M3 - Article

C2 - 14586481

AN - SCOPUS:10744225243

VL - 18

SP - 133

EP - 138

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -